Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioEBIT MarginEBITDA MarginEBT MarginEnterprise ValueFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

BioLineRx (BLRX) Gross Margin (2024 - 2025)

Historic Gross Margin for BioLineRx (BLRX) over the last 2 years, with Q3 2025 value amounting to 80.33%.

  • BioLineRx's Gross Margin fell 30400.0% to 80.33% in Q3 2025 from the same period last year, while for Sep 2025 it was 50.69%, marking a year-over-year decrease of 355200.0%. This contributed to the annual value of 67.99% for FY2024, which is 449100.0% up from last year.
  • According to the latest figures from Q3 2025, BioLineRx's Gross Margin is 80.33%, which was down 30400.0% from 76.32% recorded in Q2 2025.
  • BioLineRx's Gross Margin's 5-year high stood at 86.67% during Q1 2025, with a 5-year trough of 48.17% in Q4 2024.